Singulex Files For IPO

Alameda-based Singulex, a developer of diagnostics tests for diagnosing and monitoring chronic diseases, has filed for an IPO, saying that it is looking to raised up to $86.25M on the New York Stock Exchange. The firm, whose initial tests are focused on cardiovascular diseases, said it is looking to list as SGLX. The firm's IPO is being underwritten by UBS Investment Bank, Piper Jaffray, William Blair, and Leerink Swann. The firm is venture backed by Fisk Ventures, JAFCO Co. Ltd, OrbiMed Advisors, and Prolog Ventures.